VIDEO: CAR T-cell therapy ‘showed efficacy’ in prostate cancer subgroup
Healio spoke with Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, about a study evaluating the use of a chimeric antigen receptor T-cell therapy in a subgroup of patients with prostate cancer.
The study, which was presented by Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, at the 2022 ASCO Genitourinary Cancers Symposium, evaluated the use of an autologous CAR-T cell therapy that targeted prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer.
According to Dorff, the phase 1 results “clearly showed efficacy” and included a dataset from a patient who had radiographic response to treatment, PSMA positron emission tomography response, PSA response, and biopsies that demonstrated tumor eradication and infiltration of T cells.
Dorff noted that the presentation included “really robust data showing that this PSMA-targeted CAR-T can induce a really big remission, and we’re hoping it will stay durable.”
She added that “there’s already a few months of durability in the abstract, but [it’s] just exciting to see that not one CAR-T construct, but two separate CAR-T constructs have potential in prostate cancer,” referencing data she presented at the meeting on the use of a PSCA-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.
Collapse
Read more about